Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Inventors

Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Changgeng

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11597732-B2

Patent

Publication Date

2023-03-07

Expiration Date


Abstract

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Core Innovation

The disclosure provides multiple specific compound embodiments represented by chemical structure images and associated chemical file references. The compounds share heteroaromatic scaffold variation, including deazapurine, thienopyrimidine, furopyrimidine, and substituted thieno[3,2-d]pyrimidine derivatives, with morpholine, piperazine, indazole, pyridine-like, pyrimidine-like, and other heterocycle-containing scaffolds. The embodiments include sulfur-containing core linkage, fused bicyclic or fused nitrogen-rich ring systems, and substituent variation on the core and terminal aromatic region.

Several embodiments include zinc-binding or hydroxyamide/carboxamide motifs, including N-hydroxy pyrimidine-5-carboxamide derivatives, N-hydroxyacrylamide, hydroxamic acid, and HO–NH–C(=O) or HO–C(=O)–NH representations. The disclosure also includes sulfonamide, sulfonyl, carboxamide, carboxylic acid, ester, thioether, halogen, nitro, amino, hydroxyl, alkyl, methoxy, fluoro, chloro, nitrile, and carboxyl substituent variations, together with pharmaceutically acceptable salts, prodrugs, solvates, hydrates, geometric isomers, enantiomers, diastereomers, and racemates where stated.

The compounds are presented through specific compound embodiments identified by image and chemical file references, and in some cases by enumerated labeled chemical groups and depicted rings. The invention further frames these compounds as PI3K inhibitors and, in some embodiments, as compounds that can act as HDAC inhibitors and optionally as MMP and/or mTOR inhibitors, with therapeutic context provided for disease-related pathway modulation and inhibitory activity.

Claims Coverage

The consolidated claim coverage centers on compounds selected from a group and narrowed to specific chemical embodiments. Across the provided partial claim sets, the independent coverage is supported by multiple scaffold families and recurring claim features, with a total of four to six recurring inventive features depending on the scaffold family and claim set. The claim excerpts emphasize specific compound identities, substituted chemical structures, and embodiments defined by image, CDX, MOL, or other structure-file references, sometimes together with enumerated chemical groups and rings.

Zinc-binding PI3K inhibitor scaffold families

Compounds based on deazapurine, thienopyrimidine, and furopyrimidine scaffolds, including zinc binding through a zinc binding moiety and B/C linker concept.

Specific N-hydroxy pyrimidine-5-carboxamide and thieno[3,2-d]pyrimidine embodiments

Specific compound embodiments on a morpholino-thieno[3,2-d]pyrimidine scaffold and related substituted thieno[3,2-d]pyrimidine derivatives.

Compound selected from a group

A compound selected from the group consisting of the disclosed compound embodiments, with dependent claims refining the selected member.

Specific compound identity via structure files or images

Particular chemical structures are defined by associated image and chemical file references, including TIF, CDX, MOL, and EMI/US identifier sets.

Substituted chemical structures

The selected compounds are further defined as substituted chemical structures shown in the provided representations.

Enumerated labeled chemical groups and rings

Some embodiments are characterized by constituent labeled chemical groups/atoms and depicted rings, including morpholine-like, piperazine-like, pyrimidine-like, and other ring motifs.

Overall, the claims cover selected compounds from disclosed groups and narrow them to specific scaffold embodiments and substitution patterns. The recurring claim-level features are scaffold selection, structure-file-defined identities, substituted structure definitions, and, in some excerpts, labeled group and ring enumerations.

Stated Advantages

A single molecule can combine PI3K inhibition with HDAC inhibition, and optionally MMP/mTOR inhibition, via zinc binding.

Potential synergy is discussed for the combined activity in a single molecule compared with separate PI3K plus HDAC combinations.

PI3 kinase inhibitory activity is asserted for certain compound embodiments.

HDAC inhibitory activity is asserted for certain compound embodiments.

Possible mTOR inhibitory activity is referenced for certain compound embodiments.

Documented Applications

Treating PI3K-related diseases, including cancer.

Preventing and/or treating cancers.

Preventing and/or treating hematological cancers.

Preventing and/or treating lymphopenia.

Preventing and/or treating other proliferative or immune/apoptosis-related diseases.

Use as a medicament.

Use in combination therapy.

Use as part of a pharmaceutical composition including solvate/hydrate/pharmaceutically acceptable salt concepts and formulation/administration concepts.

The compounds are described in connection with inhibitory activity, including PI3 kinase inhibitory activity, HDAC inhibitory activity, and possible mTOR inhibitory activity.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.